Cardiac safety of liposomal anthracyclines

被引：44

作者：

Batist, Gerald ^{[1
]}

机构：

[1] McGill Univ, Sir Mortimer B Davis Jewish Hosp, Ctr Expt Therapeut Canc, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada

来源：

CARDIOVASCULAR TOXICOLOGY | 2007年 / 7卷 / 02期

关键词：

myocet; pegylated liposomal doxorubicin; trastuzumab; cardiotoxicity;

D O I：

10.1007/s12012-007-0014-4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Anthracyclines remain amongst the most active therapeutic agents for breast cancer treatment. Rather than being supplanted by novel targeted agents, they are being combined with them in various schedules. Furthermore, anthracyclines themselves are still being studied, with increasing biological understanding of their biological activity and molecular targets. A cardiac safe formulation of doxorubicin opens a number of interesting therapeutic opportunities. Liposomal doxorubicins appear to provide this opportunity.

引用

收藏

页码：72 / 74

页数：3

相关论文

共 10 条

[1]

BASELGA, 2005, PHASE 2 TRIAL TAXOL

[2] Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer [J].

Batist, G ;

Ramakrishnan, G ;

Rao, CS ;

Chandrasekharan, A ;

Gutheil, J ;

Guthrie, T ;

Shah, P ;

Khojasteh, A ;

Nair, MK ;

Hoelzer, K ;

Tkaczuk, K ;

Park, YC ;

Lee, LW .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (05) :1444-1454

[3] Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis [J].

Batist, Gerald ;

Harris, Lyndsay ;

Azarnia, Nozar ;

Lee, Lily Waiyee ;

Daza-Ramirez, Pascual .

ANTI-CANCER DRUGS, 2006, 17 (05) :587-595

[4] Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: A multicenter phase II trial [J].

Chia, Stephen ;

Clemons, Mark ;

Martin, Lee-Ann ;

Rodgers, Angela ;

Gelmon, Karen ;

Pond, Gregory R. ;

Panasci, Lawrence .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :2773-2778

[5] Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma [J].

Harris, L ;

Batist, G ;

Belt, R ;

Rovira, D ;

Navari, R ;

Azarnia, N ;

Welles, K ;

Winer, E .

CANCER, 2002, 94 (01) :25-36

[6] Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:: Danish Breast Cancer Cooperative Group [J].

Knoop, AS ;

Knudsen, H ;

Balslev, E ;

Rasmussen, BB ;

Overgaard, J ;

Nielsen, KV ;

Schonau, A ;

Gunnarsdóttir, K ;

Olsen, KE ;

Mouridsen, H ;

Ejlertsen, B .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) :7483-7490

[7]

Overmoyer Beth, 2005, Clin Breast Cancer, V6, P150, DOI 10.3816/CBC.2005.n.017

[8] HER2 and responsiveness of breast cancer to adjuvant chemotherapy [J].

Pritchard, KI ;

Shepherd, LE ;

O'Malley, FP ;

Andrulis, IL ;

Tu, DS ;

Bramwell, VH ;

Levine, MN .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (20) :2103-2111

[9] Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. [J].

Slamon, DJ ;

Leyland-Jones, B ;

Shak, S ;

Fuchs, H ;

Paton, V ;

Bajamonde, A ;

Fleming, T ;

Eiermann, W ;

Wolter, J ;

Pegram, M ;

Baselga, J ;

Norton, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) :783-792

[10] Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer [J].

Swenson, CE ;

Bolcsak, LE ;

Batist, G ;

Guthrie, TH ;

Tkaczuk, KH ;

Boxenbaum, H ;

Welles, L ;

Chow, SC ;

Bhamra, R ;

Chaikin, P .

ANTI-CANCER DRUGS, 2003, 14 (03) :239-246